Pharmacogenomic data further implicate polymorphisms in immune regulatory loci as modulators of trogocytic efficiency and specificity, highlighting the potential for genotype-informed therapeutic strategies targeting the HLA-G axis in SLE (Agbakwuru and Wetzel, 2024). This evidence concerns the gene HLA-G and systemic lupus erythematosus.